A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines
Clinical trial NCT03907878 · COMPLETED
Trial details
- NCT number
- NCT03907878
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-13
- Primary completion
- 2022-01-26
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.